AlphaMedixTM: Positive Phase 2 Results for the Treatment of GEP-NETs

Sanofi-Avantis and Orano Med announced that their investigational therapy AlphaMedixTM (212Pb-DOTAMTATE) has met primary efficacy endpoints in a Phase 2 clinical trial. This trial aims to evaluate its impact on difficult-to-treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The results showed clinically significant benefits in terms of progression-free survival and overall survival, in addition to an acceptable safety profile. This innovative therapy targets somatostatin receptors, which are present in the majority of NETs.

In February 2024, AlphaMedixTM had already received Breakthrough Therapy Designation from the FDA, highlighting its promising potential. Discussions with health authorities will continue to quickly make this therapeutic option available to patients. The full results will be presented at the ESMO 2025 congress.